Prophylaxis in factor IX deficiency product and patient variation.
about
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BClinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Treatment of hemophilia B: focus on recombinant factor IX.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Haemophilia B: Christmas disease.Haemophilia B: current pharmacotherapy and future directions.Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.The role of Rixubis™ in the treatment of hemophilia B.Emerging drugs for hemophilia B.Current management of hemophilia B: recommendations, complications and emerging issues.Longer-acting clotting factor concentrates for hemophilia.Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization.Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy.Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
P2860
Q28078281-B79515F1-D213-4FD6-A521-93D4C778165CQ34045763-C6AB9CB7-768C-4F80-8BE3-2451BBEB604DQ34329068-7A01A0E3-FEBB-4E5B-BA57-0DBCAFBAFAF7Q35692016-B1AAFE02-AD95-4DC9-AECB-BC0C693BC299Q36221979-C5FAD53A-3934-4856-8F57-08F064159CF4Q38040458-0B4874F1-2101-46E9-BE4A-9BBF37CCB933Q38115812-C9A3A70E-38F8-4C3E-9464-C9F8D82E6CB9Q38210808-6AC4D170-D31A-4D23-85EC-E6C03492BDA3Q38237476-AFF116F9-982B-4F2C-B783-13CCEFAEB547Q38238972-B90B4413-8E19-4A10-85FF-A7696C9644BFQ38543283-834641EB-1384-4F86-83BF-8713ED18252AQ40066317-9DBF0906-A8C6-45D9-9860-92C83944AB1FQ42285404-9A8D195C-ADF1-42C9-B8B1-71BE79F9717EQ43591074-427C78B5-8E39-4B36-B954-3A370AD61279Q44051815-6393F333-8262-4A84-9956-59540F6007C2Q45856730-405A440C-8B6F-494C-892C-87FFB359CA7AQ45861492-99CDDCEE-670E-4B82-BD47-6267F43C0885Q45865134-07CAEABF-1E16-4611-8B3A-897E5FB95045Q45866870-E60512ED-3D88-4110-88DD-02F5E0D6CEE1Q45869388-1301FCC1-65F9-474C-8B74-D355CE2A66A1Q45872775-BD1F4A8F-38BB-494A-947D-E4AC2A8687F4Q45887347-D860A238-63EF-47A6-8970-F6D16B9B0CED
P2860
Prophylaxis in factor IX deficiency product and patient variation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Prophylaxis in factor IX deficiency product and patient variation.
@en
Prophylaxis in factor IX deficiency product and patient variation.
@nl
type
label
Prophylaxis in factor IX deficiency product and patient variation.
@en
Prophylaxis in factor IX deficiency product and patient variation.
@nl
prefLabel
Prophylaxis in factor IX deficiency product and patient variation.
@en
Prophylaxis in factor IX deficiency product and patient variation.
@nl
P2093
P2860
P1433
P1476
Prophylaxis in factor IX deficiency product and patient variation.
@en
P2093
B Schwartz
C T Kisker
Mononine Study Group
P2860
P304
P356
10.1046/J.1365-2516.2003.00751.X
P577
2003-05-01T00:00:00Z